MARIZEV® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved MARIZEV® (omarigliptin) 25 mg and 12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes. Japan is the first country to have approved omarigliptin……….http://www.mercknewsroom.com/news-release/prescription-medicine-news/marizev-omarigliptin-mercks-once-weekly-dpp-4-inhibitor-type
syn…….http://newdrugapprovals.org/2014/04/18/omarigliptin-mk-3102-in-phase-3-for-type-2-diabetes/
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE
Join me on Facebook 
Googleplus![]()
amcrasto@gmail.com
amcrasto@gmail.com/////////////MARIZEV, (Omarigliptin), Merck’s, Once-Weekly, DPP-4 Inhibitor, Type 2 Diabetes, Approved, Japan
Filed under: DIABETES, Japan marketing, Japan pipeline Tagged: Approved, DPP-4 inhibitor, JAPAN, MARIZEV, Merck’s, OMARIGLIPTIN, Once-Weekly, TYPE 2 DIABETES
